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MYELOPROLIFERATIVE DISORDERS
The  myeloproliferative  disorders  (MPD)  are  a  group  of 
haematological conditions where there is a primary disorder at 
the level of the multi-potent haematopoietic stem cell leading 
to increased production in one or more blood cell types. The 
three main disorders in the group are polycythaemia vera (PV), 
essential thrombocythaemia (ET) and idiopathic myelofibrosis 
(IMF). PV is characterised by an increase in red cells, white 
cells  and  platelets  and  clinically  a  plethoric  appearance, 
itch and splenomegaly. The disease can be complicated by 
thromboembolic phenomena and haemorrhage and in the end 
stages can progress to myelofibrosis and acute leukaemia. ET 
is characterised by an increased platelet count. Clinically it 
is frequently asymptomatic but the thromboembolic events 
may lead to disease detection. There is a small propensity to 
progress to myelofibrosis and acute leukaemia which may be 
influenced by the treatment modalities used. IMF is defined 
by  a  leukoerythroblastic  blood  picture,  splenomegaly  and 
bone marrow fibrosis. The blood picture includes anaemia, 
thrombocythaemia or thrombocytopenia and variable white 
cell counts. The disease frequently progresses inexorably to 
transfusion dependent anaemia, symptomatic splenomegaly 
and transformation to acute leukaemia.
A  number  of  different  biological  phenomena  have  been 
described  in  haematopoietic  cells  from  PV  patients  and 
other MPDs, the majority of which involve dysregulation of 
key signalling mediators. The key molecular events in the 
pathogenesis of these disorders have been poorly defined 
to date, except in the case of Chronic Myeloid Leukaemia 
(CML)  with  the  associated  characteristic  chromosomal 
translocation ‘the Philadelphia chromosome’ and associated 
rearranged gene BCR – ABL.
PV progenitor cells have been shown to grow in the absence 
of  added  erythropoietin,  so  called  endogenous  erythroid 
colony  (EEC)  formation  1  and  to  be  hypersensitive  to  a 
variety  of  other  cytokines  including  insulin-like  growth 
factor-1.2 EEC formation however is not specific to PV and 
is also identified in other MPDs. Other properties include 
increased  expression  of  the  inhibitor  of  apoptosis  Bcl-xL 
in the absence of Epo in PV erythroid cells suggesting that 
deregulated  expression  of  Bcl-xL  may  contribute  to  the 
erythropoietin dependent survival of erythroid lineage cells 
in PV .3 Expression of the thrombopoietin receptor, Mpl, by 
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platelets  and  megakaryocytes  from  patients  with  PV  has 
been shown to be reduced compared to normal controls.4 
This again is not specific to PV however and can occur in 
other MPDs. RNA synthesis from the polycythaemia rubra 
vera 1 (PRV-1) gene has been found to be over expressed in 
PV granulocytes.5 Erythroid colonies from PV patients have 
been shown to contain a hyperactive membrane-associated 
tyrosine phosphatase PTP-MEG2, although the exact role in 
erythrogenesis requires further investigation.6 
Under normal conditions binding of the Epo receptor by its 
ligand induces rapid phosphorylation of Akt and subsequent 
stimulation  of  survival  pathways  for  erythroid  colonies. 
Erythroid cells derived from individuals with PV have been 
shown to demonstrate increased phosphorylation of Akt/PKb 
and  also  Glycogen  synthase  Kinase  3.7 This  contributes 
to  inherent  survival  properties  of  the  erythroid  cells. 
Microarray analysis has identified candidate genes involved 
in  the  pathophysiology  of  PV  including  the  transcription 
factor NF-E2 (Nuclear Factor (Erythroid-derived 2)). This 
has been shown to be over expressed in the bone marrow 
megakaryocytic,  erythroid  and  myeloid  precursors  of  PV 
subjects.8
Over 50 years ago Dameshek  9 linked together the recognised 
disorders  PV,  chronic  myeloid  leukaemia  and  IMF  and 
speculated on the common myelostimulatory factors. In the 
early 1970s chronic myeloid leukaemia was separated as a 
distinct clonal disorder defined by a single chromosomal and 
latterly gene rearrangement (BCR/ABL).10 Until very recently 
the other MPDs continue to be separated and diagnosed on 
the basis of their clinical and laboratory findings (Table I). 
However, recent molecular findings in the JAK2 gene are 
common to all these disorders.
JANUS KINASE 2
The JAK2 gene was first cloned in 1989  11 and is a member of a 
family of four Janus kinases 1, 2 and 3 and tyrosine kinase  2. 
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Table  I
Diagnostic criteria for common myeloproliferative disorders
           
              Polycythaemia Vera        Essential Thrombocythaemia    Idiopathic Myelofibrosis
A1 Raised Red Cell 
mass (>25%  above 
mean predicted value) 
or Hct ≥ 0.6 males;
≥ 0.56 females
A2 Absence of 
cause for secondary 
erythrocytosis
1.	 Platelet Count > 600 x 10 9/l *
NECESSARY CRITERIA
A) Diffuse Bone Marrow Fibrosis
B) Absence of Philadelphia Chromosome or 
BCR-ABL transcript in peripheral blood cells.
A3 Palpable 
splenomegaly
A4 Clonality marker 
i.e acquired abnormal 
marrow karyotype
2.	 No evidence of overt polycythaemia/
polycythaemia masked by co-existing 
Iron deficiency
OPTIONAL CRITERIA
(i)  Splenomegaly of any grade
(ii) Anisopoikilocytosis with tear 
     drop erythrocytes
B1 Thrombocytosis
     (platelet count
     > 400 x 109/l)
B2 Neutrophil 
Leucocytosis 
(neutrophil count >10 
x 109 in non smokers; 
>12.5 x109 in smokers)
3.	 Absence of a Philadelphia   
chromosome
(iii)  Presence of circulating         
        immature myeloid cells
4.	 Absence of peripheral blood 
and/or marrow appearances of 
myelodysplasia or myelofibrosis
(iv)  Presence of circulating 
        erythroblasts
B3 Splenomegaly
(demonstrated on 
isotope/ultrasound 
scanning)
B4 Characteristic BFU-
E growth or reduced 
serum erythropoietin
5.	 No known cause of reactive 
thrombocytosis. Care should be taken 
to exclude iron deficiency in pre-
menopausal women
(v)  Presence of  clusters of 
       megakaryoblasts and 
      anomalous megakaryocytes
       in bone marrow sections.
(vi)  Myeloid metaplasia
Diagnosis
A1+A2+A3 or A4 establishes PV A1+A2+any 2 B 
Criteria establishes PV
Adapted from British Committee  for Standards in 
Haematology Guidelines on Polycythaemia36
*In asymptomatic patients the platelet  
count should be observed for a period.
Diagnosis is made if all above 5 criteria 
are met.
Adapted from diagnostic criteria in PT-1 trial co-
ordinated by UK MPD group38.
Diagnosis of IMF if:
The two necessary criteria (designated A and 
B) are present with optional criteria as follows
(1)  any two other features if splenomegaly 
present 
(2)  any four optional criteria when 
splenomegaly absent.
Adapted from Italian Consensus on 
Diagnostic Criteria for Myelofibrosis39.©  The Ulster Medical Society, 2006.
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It was originally named ‘just another kinase’ but the protein 
group was renamed Janus kinases after the Roman God of 
gates and passages. These non receptor kinases have two 
similar ‘active’ and ‘inactive’ domains and this is reminiscent 
of the God Janus who had the ability to look simultaneously 
in two directions.
Each  JAK  has  an  active  tyrosine  kinase  domain,  JAK 
homology  1(JH1),  a  catalytically  inactive  pseudokinase 
domain, JAK homology 2 (JH2), a SRC homology 2 domain 
(SH2),  and  an  amino  terminal  FERM  (4-point-1,  Erzin, 
Radixin, Moesin) homology domain where binding to type 
1  cytokine  receptors  takes  place. The  interactions  of  the 
JAK2 FERM domain also comprises a role in trafficking of 
the EPO receptor (EPOR) cytoplasmic domain to the cell 
surface.12 Under normal physiological circumstances when 
a ligand (for example erythropoietin) binds with a receptor 
a  conformational  change  occurs  (see  fig  1).  The  JAK2 
protein  then  makes  contact  with  the  cytoplasmic  domain 
of the receptor where it catalyses tyrosine phosphorylation. 
This  primarily  leads  to  the  recruitment  of  STAT  (signal 
transducer and activator of transcription) molecules which 
are then phosphorylated, homodimerise and translocate to 
the nucleus where they act as transcription factors. Tyrosine 
phosphorylation also modifies other key regulatory events 
involved in cytokine signalling pathways.
Fig 1.  Diagram illustrating Functional JAK STAT Pathway
  This  “JAK  STAT”  pathway  appears  to  be  ubiquitous 
amongst  vertebrates.  Following  ligand  binding  the 
activated JAK2 protein catalyses tyrosine phosphorylation 
in the cytoplasmic domain of the receptor and also leads to 
phospharylation of the Signal Transducers and Activators 
of Transcription (STATS).
  Phosphorylation  of  STAT  leads  to  dimerisation  via 
conserved Src homology 2 (SH2) domains. Translocation 
of these dimers to the nucleus then occurs facilitated via 
Nucleoprotein Interactor 1 (NPI -1). Subsequent regulation 
of  gene  expression  following  interaction  with  DNA 
response elements occurs. This leads to a transcriptional 
response. There is also interaction with the RAS/MAPK, 
Pl-3 K and Akt downstream pathways.
  Under normal conditions the enhanced gene expression is 
under complex negative feedback mechanisms including 
amongst others the production of the negative regulator 
Suppressors of Cytokine Signalling( SOCS).
The JH2 domain is a non catalytic pseudokinase and has 
several crucial regulatory functions.13 It appears that in the 
absence of ligand binding it has autoinhibitory properties, 
most  likely  manifest  by  a  JH2/JH1  interaction,  and  if 
an  alteration  in  this  area  occurred  dysregulation  of  this 
autoinhibition  would  result.  It  also  appears  that  maximal 
JAK2 activity in response to cytokines requires an intact JH2 
region.
In a short period in early 2005 four different groups described 
an identical mutation in  JAK2 V617F in large numbers of 
patients with MPDs.14-17 Although all groups arrived at the 
same result they approached it by different methods. The 
Vainchenker group, who are acknowledged to have made 
the discovery first, approached it from the point of view of 
the underlying biology of the disease.14 They had previously 
observed that inhibitors of JAK2 and other kinases interfered 
with the erythropoietin independent differentiation in PV .18 
Therefore they looked at potential mechanisms leading to the 
formation of EECs.
Identifying JAK2 as a potential candidate gene, and aware of 
its role as an upstream signalling molecule directly linked to 
the erythropoietin receptor, they focussed attention on this 
tyrosine kinase. They discovered that down regulating JAK2 
expression via the introduction of short interfering RNA led 
to a marked inhibition of EEC formation in individuals with 
PV . This obviously alerted the investigators to the key role 
of JAK2 in the formation of EEC and prompted sequencing 
of the coding exons and intron – exon junctions of the gene 
in three patients with PV and in two normal controls. Two 
of the individuals with PV demonstrated the presence of the 
JAK2 V617F mutation. (fig 2) In a further, larger group of 
patients with PV the mutation was present in 88% of cases. 
In all of the controls, in addition to all 35 samples of patients 
diagnosed with a secondary erythrocytosis, only wild type 
JAK2 was detected.
The mutation was shown to be acquired, as it was present 
in the myeloid lineage but absent in T cells. This group also 
identified the ability of the mutated JAK2 to spontaneously 
activate  downstream  STAT  mediated  transcription  in  the 
absence of the ligand erythropoietin. This is in contrast to 
the inability of wildtype JAK2 to mediate such events. There 
was also activation of the ERK/MAP kinase and P13K/AKT 
pathways in the absence of alternative cytokine stimulation. In 
conclusion, the auto-inhibitory activity of JAK2 was disrupted 
by the presence of this V617F mutation. 
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Fig 2.  Diagram of JAK2 Domains highlighting main roles and 
indicating approximate location of V617F Mutation.
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Skoda’s  15 group followed on from previous work where they 
had  identified  loss  of  heterozygosity  (LOH)  on  the  short 
arm of chromosome 9 in a proportion of MPD patients via 
genome wide microsatellite screening. This suggested that 
9p may harbour a pathogenic mutation. They initally utilised 
10 microsatellite markers covering chromosme 9p and found 
9p LOH in granulocytes derived from patients with MPDs 
in 21% (51 /244) of cases and in no control cases, including 
CML. All  51  patients  with  9p  LOH  possessed  the  JAK2 
V617F mutation. Further investigation found the mutation 
in 65% of patients with PV of whom 27% had an acquired 
homozygous mutation and 38% a heterozygous mutation.
Dysregulation of key tyrosine kinases is paramount to the 
pathogenesis of many cancers, including CML. This prompted 
further in depth searches for mutations in tyrosine kinases 
in the conventional myeloproliferative disorders. Gilliland’s 
group16 undertook a search for mutations of tyrosine kinases 
using high-throughput sequence analysis and found the JAK2 
V61F mutation. As part of a large study looking at protein 
kinase genes in MPDs, Green’s group17 found the mutation in 
57% of individuals with ET, 50% of individuals with IMF and 
97% of those with PV . It was detected in both granulocyte-
macrophage  and  erythroid  colonies  and  intriguingly  was 
present in all EECs, demonstrating a link with growth factor 
hypersensitivity.
The  JAK2  V61F  mutation  accounts  for  some  of  the 
abnormalities described in PV although the molecular events 
linking the mutation with the biological parameters require 
further delineation. The JH2 domain is a pseudokinase and 
possesses autoinhibitory properties which prevent receptor 
phosphorylation.  From  modelling  studies,  the  highly 
conserved valine at position 617 is predicted to lie on the 
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Fig 3.  Tetra primer ARMS PCR
  •  Tetra Primer Amplification Refractory Mutation Screening Polymerase Chain Reaction – ARMS-PCR-is an extremely efficient 
detection method of single nucleotide polymorphisms (SNPS).
  •  It consists of two pairs of primers – to amplify wildtype and mutant respectively.
  •  Two amplification allele-specific reactions occur in opposite directions, simultaneously.
  •  The mismatch is in the middle of the inner primers in contrast to conventional ARMS PCR.
  •  There is the outer forward primer, the forward inner wildtype primer, the reverse outer primer and the reverse inner mutant 
specific primer.
  •  It requires two temperature programs during the PCR reaction.
  •  Due to the positioning of the outer primers at varying distance from the site of the mutation there is the generation of three 
fragments in this example in a heterozygote: two small allele specific fragments and a large control PCR product.
  •  DNA Fragments can be distinguished via electrophoresis on agarose gel.©  The Ulster Medical Society, 2006.
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upper surface of the N-terminal lobe of the JH2 domain. 
Substituting the valine for a large phenlyalanine destabilises 
the  fold  of  the  domain.16  Therefore  the  presence  of  the 
mutation would lead to a JAK2 which is constitutively active. 
Interestingly, in heterozygotes there appears to be competition 
between the wild-type and mutant genes.
Haematopoietic  stem  cells  from  MPD  patients  are 
hypersensitive to a range of growth factors and use JAK2 
for signalling. Observations suggest a disruption of signal 
transduction  downstream  of  JAK2  including  constitutive 
activation  of  STAT3,20  up-regulation  of  the  anti-apoptotic 
protein Bcl-xL
3 and increased AKT activity.7 Death receptor 
stimulated apoptotic pathways also appear disrupted in JAK2 
V617F PV derived erythroblasts with deregulated expression 
of the short isoform of c-FLIP  21 which fundamentally plays an 
essential role in the normal homeostatic apoptotic cascade.
DETECTION METHODS
The JAK2 V617F mutation in MPDs can be detected by a 
variety of methods. The simplest method is to isolate DNA 
from whole blood leukocytes and use PCR-direct sequencing. 
However, since the mutation is acquired and restricted to the 
myeloid lineage this method has a sensitivity of between 
20 to 30%. By implication the JAK2 V617F mutant clone 
would have to constitute a significant proportion of the total 
leukocyte population to be detectable by this method.
Ficoll  gradient  centrifugation  can  be  used  to  isolate 
mononuclear  cells,  with  subsequent  separation  into 
granulocyte/macrophage lineages and lymphocytes. Methods 
to ensure an absence of gross contamination of the fractions 
should  be  utilised,  for  example  magnetic  sorting/flow 
cytometry.  Isolation  of  DNA  from  the  fractions  can  then 
occur and direct sequencing methods instituted. This allows 
detection of an acquired JAK2 V617F mutation in cells of 
myeloid lineage.
Amplification Refractory Mutation Screening (ARMS) PCR 
permits a single base change to be detected under ideal PCR 
conditions. This is ideal for detection of the single base G → T 
transversion associated with the JAK2 mutation in question. 
The ARMS-PCR technique (fig 3) uses 4 primers as follows; 
a forward outer primer, a reverse outer primer, a forward inner 
wild type specific primer and a reverse inner mutant specific 
primer. The forward primer from one set and the reverse from 
the other are able to amplify a positive control band. The 
other two primers span the site of the JAK2 V617F mutation. 
Therefore in the presence of the JAK2 mutation the reverse 
inner mutant specific primer and the forward outer primer 
bind to give a fragment of 279 bp. In the presence of wild-type 
JAK2 the reverse outer primer and the forward inner wild-type 
specific primer produce a fragment of 229bp. Performing a 
dilution series indicates the level of sensitivity of ARMS-
PCR to be 1-2 %.22 The assay allows discrimination between 
homozygous and heterozygous individuals with the JAK2 
V617F mutation and has a key role in acting as a reliable 
screening test for the presence or absence of the mutation in 
individuals with MPDs.
Although ARMS-PCR can indicate whether an individual 
is  homozygous  or  heterozygous  for  the  V617F  JAK2 
mutation it does not quantify the ratios of the wild type and 
mutant alleles. This also applies to PCR-direct sequencing. 
Pyrosequencing which uses a quantitative technique originally 
designed for the detection of single nucleotide polymorphisms 
(SNP) has been developed for the detection of the G1849T 
JAK2  mutation,  providing  accurate  allele  ratios.23, 24  This 
technique is unique in that it provides a quantitative result for 
each allele. Pyrosequencing entails amplification by PCR of 
exon 12 of JAK2, with a set of primers where one is labelled 
with a biotin tag. Single-stranded PCR products are prepared 
post PCR. Any biotin tagged single stranded DNA molecules 
are then specifically isolated by capture with streptavidin 
beads and genotypes are determined using the SNP software, 
which allows allele frequency quantification and scoring of 
individuals as homozygous when the mutant allele is greater 
than 50%.
CLINICAL CORRELATES
Other groups have proceeded to look at their series of patients 
and identified similar rates of the presence of the mutation in 
the various disease groups (Table II).14-17, 22-25 Of interest is 
that the mutation is found extremely rarely in those with no 
identified cause of erythrocytosis and screening is therefore 
of benefit for the detection of clonal disease.26 The presence 
of the JAK2 V617F mutation has been correlated with other 
described biological phenomena such as PRV1 expression 
and EEC formation.27 Patients who are JAK2 V617F mutation 
heterozygous or homozygous have been shown to express 
higher  levels  of  NF-E2  compared  to  mutation  negative 
individuals.28
Those  who  are  homozygous  for  the  mutation  may  have 
different or more advanced disease compared to those who 
are heterozygous. Kravolics  15 showed that those who were 
homozygous  had  a  longer  duration  of  disease  and  were 
more  likely  to  develop  secondary  myelofibrosis. Tefferi  29 
demonstrated that in PV those possessing the homozygous 
JAK2 mutation tended to have higher haemoglobin levels, 
an increased incidence of pruritis and higher rates of fibrotic 
complications.
The  significance  of  considering  cases  with  a  very  small 
percentage of JAK2 mutant positive clones as being “truly” 
JAK2 V617F positive remains unclear. Obviously one needs 
to consider what ‘cut off’ value we use to distinguish those 
possessing the mutation from those classified as mutation 
negative.  This  is  of  importance  if  the  presence  of  the 
JAK2 V61F  mutation  is  to  become  paramount  within  the 
classification system of MPDs. Familial MPDs, including 
polycythaemia,30 have been well documented and it appears 
that even in these rare cases, the JAK2 mutation appears to be 
somatic rather than germ-line in nature.
The impact of the mutation in IMF, from a clinical stance, 
appears  somewhat  less  well  defined.  In  a  large  study  of 
myelofibrosis, Campbell et al  31 showed that patients with the 
JAK2 V617F  mutation had higher neutrophil and white cell 
counts compared to patients without the mutation and overall 
tended to have a poorer prognosis. Tefferi et al  32 looked for 
the mutation in a variety of patients with myelofibrosis and 
found that the mutation was more likely to be present in 
patients with a previous history of PV compared to de novo 
MF. The presence of the JAK2 V617F mutation in this fairly 
large cohort of 157 patients did not appear to have prognostic 
significance.
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Table II
Some reported incidences of JAK2 V61F mutation in myeloproliferative disorders
Investigators
Green 17 Vainchenker 14 Gilliland16 Skoda 15 Tefferi24 Cross22 Zhao25 Jelinek 23 Disorder
PV 97% 88% 74% 65% 81% 83% 86%
ET 57% 43% 32% 23% 41% 30%
IMF 50% 43% 35% 57% 43% 95%
SM 25% 0%
CNL 17% 33%
HES 0% 2%
UN 20%
MDS 5% 1.5%
CMML	 3% 13%
The MRC-PT-1 prospective study of ET allowed comparison 
of mutation positive and negative patients.33 Those with the 
mutation had features resembling PV , higher haemoglobin, 
higher  neutrophil  counts,  more  venous  thrombosis  and 
a higher rate of transformation to PV but they had lower 
serum erythropoietin levels and ferritin levels. JAK2 V617F 
positive  patients  appeared  to  more  sensitive  to  treatment 
with hydroxycarbamide but not anagrelide. Another series 
of ET patients showed that those with the mutation were 
more likely to transform to PV .34 These findings call into 
question the separation of the diseases PV and ET. There 
may be a continuum of disease with the effects of the JAK2 
V617F mutation on clinical presentation influenced by other 
modifiers including iron supply, erythropoietin suppression 
and other genetic modifiers (see fig 4).
OTHER DISEASES
The presence of the mutation has been investigated in atypical 
MPDs including systemic mastocytosis, hypereosinophilic 
syndrome,  chronic  neutrophilic  leukaemia,  unclassified 
myeloproliferative disorders .24 Of interest, McLornan et al 35 
detected the mutation in one chronic neutrophilic leukaemia 
patient with an unusual protracted course where the mutation 
may in some way influence the course of the disease. The 
mutation has been found in varying proportions of patients as 
summarised in Table II. It has been detected rarely in patients 
with  myelodysplastic  disorders.22  The  prevalence  of  the 
mutation is higher in patients with acute myeloid leukaemia 
(AML)  with  antecedent  PV  or  IMF  than  in  the  overall 
cohort.36 It has been reported rarely in other series of patients 
with AML and no patients with lymphoid leukaemia.23, 36
FURTHER QUESTIONS
The fascinating discovery of a single mutation in a wide 
spectrum  of  MPDs  has  lead  to  rapid  progress  in  the 
investigation  of  MPDs  but  leads  to  a  number  of  further 
questions. The hierarchical position of this mutation requires 
further study. It is still not clear whether the JAK2 V61F 
mutation is the primary initiating event or a secondary event 
with an as yet unknown primary event. While the presence of 
the mutation was sufficient to induce erythrocytosis in mice 
this is a manipulated experimental situation and it may not be 
sufficient to initiate disease in the human.
Classification  of  MPD  needs  revision.  The  presence  of 
the  mutation  demonstrates  a  clonal  disorder  but  splitting 
of  diseases  on  the  basis  of  clinical  characteristics 
KEY TO ABBREVIATIONS
PV: polycythemia vera, ET: essential thrombocythemia, IMF: idiopathic myelofibrosis, SM: systmemic mastocytosis, CNL: chronic neutrophilic 
leukemia, HES: hypereosinophilic syndrome, UN: unclassified MPD, MDS: myelodysplastic syndrome, CMML: chronic myelomonocytic 
leukemia.
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needs  reconsideration.  Questions  remain  about  the 
underlying  pathogenesis  in  those  with  mutation  negative 
myeloproliferative disorders. In summary, the discovery of a 
single mutation JAK2 V61F in a large number of MPD patients 
has lead to great progress in the understanding of MPDs but 
leads to many more exciting biological questions.
The authors have no conflict of interest.
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